Geir Åge Løset
Vorstandsvorsitzender bei Nextera AS
Ursprung des Netzwerks ersten Grades von Geir Åge Løset
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway.
7
| Holding Company | Miscellaneous Commercial Services | 7 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Geir Åge Løset
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | Biotechnology | Director/Board Member Founder Director/Board Member | |
BI Norwegian Business School | College/University | Undergraduate Degree Graduate Degree Graduate Degree | |
University of Oslo | College/University | Doctorate Degree Corporate Officer/Principal Undergraduate Degree | |
NYKODE THERAPEUTICS | Pharmaceuticals: Major | Chief Executive Officer Founder Chairman | |
Radiumhospitalets Forskningsstiftelse
Radiumhospitalets Forskningsstiftelse Financial ConglomeratesFinance Radiumhospitalets Forskningsstiftelse invests in companies from Nordic research institutions. It is a pre-seed investor and project developer focused on cancer. It strengthens cancer research at Rikshospitalet University Hospital, including The Norwegian Radium Hospital. It provides Oslo Cancer Cluster with the necessary infrastructure and management team, as well. The company was founded in 1986 and is headquartered in Lysaker, Norway. | Financial Conglomerates | Director/Board Member Chief Investment Officer | |
Pfizer AS
Pfizer AS Pharmaceuticals: MajorHealth Technology Pfizer AS operates as biopharmaceutical company, which engages in the development and manufacture of pharmaceutical products. It develops and produces medicines such as penicillin; vaccines; and medicines for the treatment of cancer, pain, cardiovascular disease, diabetes, mental illness, and rheumatism. The firm also offers drugs against parasites. The company was founded on November 25, 1959 and is headquartered in Oslo, Norway. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
APIM Therapeutics AS
APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Birk Venture AS
Birk Venture AS Investment ManagersFinance Birk Venture AS (Birk Venture) is an independent Scandinavian venture capital firm which was founded in 2010 by Hans Ivar Robinson. Based in Oslo, Norway, the firm focuses exclusively on the life science industry, utilizing their industry experience and international network to partner with young companies with significant growth prospects. | Investment Managers | Chief Executive Officer Private Equity Investor | |
University of Bielefeld | College/University | Doctorate Degree | |
Invitrogen Dynal AS | Chief Tech/Sci/R&D Officer | ||
Oslo Cancer Cluster NCE
Oslo Cancer Cluster NCE Miscellaneous Commercial ServicesCommercial Services Oslo Cancer Cluster NCE is an oncology research firm that specializes in developing cancer diagnostics and medicines. The private company is based in Oslo, Norway. | Miscellaneous Commercial Services | Director/Board Member | |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Sales & Marketing | |
Ernst & Young AS
Ernst & Young AS Miscellaneous Commercial ServicesCommercial Services Part of Ernst & Young Global Ltd., Ernst & Young AS is a Norwegian company that provides accounting services. The company is based in Oslo, Norway. The CEO of the company is Christin Erichsen Bøsterud. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
PHOTOCURE ASA | Medical Specialties | Director/Board Member | |
Radforsk | Chief Investment Officer | ||
Nucligen AS | Director/Board Member | ||
CIRCIO HOLDING ASA | Biotechnology | Director/Board Member | |
Rikshospitalet HF
Rikshospitalet HF Hospital/Nursing ManagementHealth Services Rikshospitalet HF operates hospitals and healthcare centers. The private company is based in Oslo, Norway. | Hospital/Nursing Management | Corporate Officer/Principal | |
Accession Therapeutics Limited
Accession Therapeutics Limited BiotechnologyHealth Technology Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors. | Biotechnology | Director/Board Member | |
AstraZeneca AS | Corporate Officer/Principal | ||
Norwegian School of Economics & Business Administration | College/University | Graduate Degree | |
BERGENBIO ASA | Pharmaceuticals: Major | Director/Board Member | |
BIOINVENT INTERNATIONAL AB | Biotechnology | Chief Executive Officer | |
Uni Targeting Research AS
Uni Targeting Research AS BiotechnologyHealth Technology Uni Targeting Research AS is a holding company that provides the biopharmaceutical industry with tools and services for mammalian cell-line based development procedures and production processes. It offers upstream solutions to reduce complementary deoxyribonucleic acid and mammalian cell-line based timelines and increase protein production yields. Its technology enables both enhanced synthesis/secretion of naturally secreted proteins, and secretion of intracellular proteins. Its services include vector improvement, tailor-made vectors, and tool proteins. The company was founded by Ian Fraser Pryme, John E. Hesketh, Albert Tauler, and Beate Stern in 2001 and is headquartered in Bergen, Norway. | Biotechnology | Director/Board Member | |
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Chief Executive Officer | |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | Biotechnology | Director/Board Member | |
Artbio AS
Artbio AS BiotechnologyHealth Technology Part of Artbio, Inc., Artbio AS is a clinical-stage radiopharmaceutical biotechnology business that works to create a new class of alpha radio ligand medicines. The company is based in Oslo, Norway. The Norwegian company was founded in 2018. The CEO is Emanuele Ostuni. | Biotechnology | Director/Board Member |
Statistik
International
Norwegen | 27 |
Dänemark | 3 |
Deutschland | 3 |
Schweden | 3 |
Vereinigtes Königreich | 2 |
Sektoral
Health Technology | 18 |
Commercial Services | 6 |
Consumer Services | 5 |
Finance | 4 |
Technology Services | 2 |
Operativ
Director/Board Member | 20 |
Corporate Officer/Principal | 13 |
Chief Executive Officer | 8 |
Founder | 6 |
Chairman | 6 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Anders Tuv | 12 |
Martin Welschof | 12 |
Hans Ivar Robinson | 11 |
Ole Henrik André Brekke | 7 |
Per-Oluf Olsen | 6 |
Thomas Andersen | 5 |
Inger Sandlie | 4 |
- Börse
- Insiders
- Geir Åge Løset
- Unternehmensverbindungen